{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:29:39Z","timestamp":1794108579654,"version":"4.8.0"},"reference-count":62,"publisher":"BMJ","issue":"2","funder":[{"name":"Chih Kuang Scholarship for Outstanding Young Physician-Scientists of Sun Yat-sen University Cancer Center","award":["CKS-SYSUCC-2023002"],"award-info":[{"award-number":["CKS-SYSUCC-2023002"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M744015"],"award-info":[{"award-number":["2023M744015"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024T171070"],"award-info":[{"award-number":["2024T171070"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"New Cornerstone Science Foundation through the XPLORER PRIZE, Young Talents Program of Sun Yat-sen University Cancer Center","award":["YTP-SYSUCC-0018"],"award-info":[{"award-number":["YTP-SYSUCC-0018"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-QL202202-0089"],"award-info":[{"award-number":["Y-QL202202-0089"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM202211017"],"award-info":[{"award-number":["SZSM202211017"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82321003"],"award-info":[{"award-number":["82321003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8240101755"],"award-info":[{"award-number":["8240101755"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425048"],"award-info":[{"award-number":["82425048"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Innovative Research Program of Sun Yat-sen University Cancer Center","award":["CIRP-SYSUCC-0004"],"award-info":[{"award-number":["CIRP-SYSUCC-0004"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2025,9,1]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Combining chemotherapy with anti-programmed cell death protein-1 (PD-1) improves clinical outcomes in oesophageal squamous cell carcinoma (ESCC), yet the underlying synergistic mechanism remains obscured. Moreover, 30\u201350% of patients still derive no therapeutic benefit from the combination strategy, highlighting the need to decipher and overcome resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We sought to investigate the mechanisms by which chemotherapy augments the responses to immune checkpoint blockade and elucidate the factors contributing to persistent resistance in non-responding patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We designed a systematic investigation involving longitudinal sampling of ESCC tissues both from patients treated with chemotherapy plus anti-PD-1 and anti-PD-1 monotherapy. The tumour microenvironment (TME) was then comprehensively characterised using single-cell transcriptomics, T cell receptor repertoire analysis, multiplex immunohistochemistry and murine models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We demonstrated that combination therapy exerted superior antitumour efficacy by mitigating immune checkpoint engagements (TIGIT-NECTIN2 and NECTIN1-CD96) between epithelial-stress tumour cells and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, thereby preventing T cells from exhaustion and boosting vitality. In non-responders, we identified a subset of tumour cells with high SLC1A3 expression, which localised at the tumour boundary and interacted with COL1A1\n                      <jats:sup>+<\/jats:sup>\n                      myofibroblastic cancer-associated fibroblasts, inducing an extracellular matrix-enriched TME that hindered the infiltration of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Inhibiting SLC1A3 significantly enhanced the efficacy of chemotherapy plus anti-PD-1, underscoring its potential as a therapeutic target.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study elucidates the synergistic mechanisms and identifies key resistance pathways underlying chemo-immunotherapy combinations in patients with ESCC, providing a scientific basis for refining future combination therapeutic regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2025-335642","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T17:20:26Z","timestamp":1758561626000},"page":"252-264","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma"],"prefix":"10.1136","volume":"75","author":[{"given":"Shujing","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, China"},{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, China"},{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoye","family":"Wang","sequence":"additional","affiliation":[{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, China"},{"name":"Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, China"},{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"He","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, China"},{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3542-0905","authenticated-orcid":false,"given":"Zhichao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, China"},{"name":"Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4697-6853","authenticated-orcid":false,"given":"Lu-Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fu","family":"Wei","sequence":"additional","affiliation":[{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, China"},{"name":"Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Nian","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Xian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, China"},{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Yan","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5086-5334","authenticated-orcid":false,"given":"Zhigang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, China"},{"name":"Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9657-4380","authenticated-orcid":false,"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, China"},{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7668-9674","authenticated-orcid":false,"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, China"},{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"2026060303500760000_75.2.252.1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.08.023"},{"key":"2026060303500760000_75.2.252.2","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026060303500760000_75.2.252.3","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12178"},{"key":"2026060303500760000_75.2.252.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2026060303500760000_75.2.252.5","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1038\/s41591-024-03088-2","article-title":"Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial","volume":"30","author":"Mo","year":"2024","journal-title":"Nat Med"},{"key":"2026060303500760000_75.2.252.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20019-0"},{"key":"2026060303500760000_75.2.252.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888"},{"key":"2026060303500760000_75.2.252.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z"},{"key":"2026060303500760000_75.2.252.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4"},{"key":"2026060303500760000_75.2.252.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380"},{"key":"2026060303500760000_75.2.252.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836"},{"key":"2026060303500760000_75.2.252.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.007"},{"key":"2026060303500760000_75.2.252.13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ccell.2023.03.016","article-title":"An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"key":"2026060303500760000_75.2.252.14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.08.426","article-title":"OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC","volume":"14","author":"Langer","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2026060303500760000_75.2.252.15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026060303500760000_75.2.252.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-022-00866-3","article-title":"Tumor microenvironment: barrier or opportunity towards effective cancer therapy","volume":"29","author":"Tiwari","year":"2022","journal-title":"J Biomed Sci"},{"key":"2026060303500760000_75.2.252.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x"},{"key":"2026060303500760000_75.2.252.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01307-2","article-title":"Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors","volume":"15","author":"Xu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026060303500760000_75.2.252.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-00990-4","article-title":"High-throughput single-\u0441ell sequencing in cancer research","volume":"7","author":"Jia","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026060303500760000_75.2.252.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.09.011"},{"key":"2026060303500760000_75.2.252.21","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1038\/s41467-024-52977-0","article-title":"Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"key":"2026060303500760000_75.2.252.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27599-5","article-title":"Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment","volume":"12","author":"Dinh","year":"2021","journal-title":"Nat Commun"},{"key":"2026060303500760000_75.2.252.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-024-01320-9","article-title":"Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma","volume":"16","author":"Ji","year":"2024","journal-title":"Genome Med"},{"key":"2026060303500760000_75.2.252.24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026060303500760000_75.2.252.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005920","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy","volume":"11","author":"Rizvi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026060303500760000_75.2.252.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02371-y"},{"key":"2026060303500760000_75.2.252.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.06.018"},{"key":"2026060303500760000_75.2.252.28","doi-asserted-by":"crossref","first-page":"100127","DOI":"10.1016\/j.xcrm.2020.100127","article-title":"CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17","volume":"1","author":"Corgnac","year":"2020","journal-title":"Cell Reports Medicine"},{"key":"2026060303500760000_75.2.252.29","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101686","article-title":"Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026060303500760000_75.2.252.30","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"2026060303500760000_75.2.252.31","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","article-title":"Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours","volume":"618","author":"Gavish","year":"2023","journal-title":"Nature New Biol"},{"key":"2026060303500760000_75.2.252.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25539-x"},{"key":"2026060303500760000_75.2.252.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2024.110130"},{"key":"2026060303500760000_75.2.252.34","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-04985-3","article-title":"RGS6 drives cardiomyocyte death following nucleolar stress by suppressing Nucleolin\/miRNA-21","volume":"22","author":"Sengar","year":"2024","journal-title":"J Transl Med"},{"key":"2026060303500760000_75.2.252.35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026060303500760000_75.2.252.36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004711","article-title":"TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy","volume":"10","author":"Chiang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026060303500760000_75.2.252.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2018.10.023"},{"key":"2026060303500760000_75.2.252.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0183-z"},{"key":"2026060303500760000_75.2.252.39","doi-asserted-by":"crossref","first-page":"10838","DOI":"10.1002\/anie.201505294","article-title":"High\u2010Throughput, Label\u2010Free Isolation of Cancer Stem Cells on the Basis of Cell Adhesion Capacity","volume":"54","author":"Zhang","year":"2015","journal-title":"Angew Chem Int Ed"},{"key":"2026060303500760000_75.2.252.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-1031"},{"key":"2026060303500760000_75.2.252.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01860-5","article-title":"Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"key":"2026060303500760000_75.2.252.42","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0002"},{"key":"2026060303500760000_75.2.252.43","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01670-1","article-title":"Targeting the tumor stroma for cancer therapy","volume":"21","author":"Xu","year":"2022","journal-title":"Mol Cancer"},{"key":"2026060303500760000_75.2.252.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06435-w"},{"key":"2026060303500760000_75.2.252.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.09.012"},{"key":"2026060303500760000_75.2.252.46","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"2026060303500760000_75.2.252.47","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"key":"2026060303500760000_75.2.252.48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026060303500760000_75.2.252.49","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.39116","article-title":"Chemotherapy-Related Toxic Effects and Quality of Life and Physical Functioning in Older Patients","volume":"6","author":"Baltussen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026060303500760000_75.2.252.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.08.013"},{"key":"2026060303500760000_75.2.252.51","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"2026060303500760000_75.2.252.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.018"},{"key":"2026060303500760000_75.2.252.53","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2012.141"},{"key":"2026060303500760000_75.2.252.54","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0637"},{"key":"2026060303500760000_75.2.252.55","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS370","article-title":"AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)","volume":"40","author":"Xu","year":"2022","journal-title":"JCO"},{"key":"2026060303500760000_75.2.252.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0004-1"},{"key":"2026060303500760000_75.2.252.57","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cac2.12538","article-title":"Conserved immuno\u2010collagenic subtypes predict response to immune checkpoint blockade","volume":"44","author":"Mei","year":"2024","journal-title":"Cancer Commun"},{"key":"2026060303500760000_75.2.252.58","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/0008-5472.CAN-24-0932","article-title":"YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer","volume":"84","author":"Song","year":"2024","journal-title":"Cancer Res"},{"key":"2026060303500760000_75.2.252.59","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"key":"2026060303500760000_75.2.252.60","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019102147","article-title":"SLC1A3 contributes to L-asparaginase resistance in solid tumors","volume":"38","author":"Sun","year":"2019","journal-title":"EMBO J"},{"key":"2026060303500760000_75.2.252.61","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2022.12.004","article-title":"Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"2026060303500760000_75.2.252.62","doi-asserted-by":"crossref","unstructured":"Xu J , Li Y , Fan Q , et al . n.d. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nat Commun 13:857. doi:10.1038\/s41467-022-28408-3","DOI":"10.1038\/s41467-022-28408-3"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2025-335642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:01:12Z","timestamp":1780581672000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2025-335642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":62,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/gutjnl-2025-335642"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2025-335642","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}